Oral upadacitinib may be a promising treatment option for patients with atopic dermatitis-type chronic hand eczema that is ...

A history of traumatic brain injury was linked to long-term cognitive decline involving speech functions, specifically where ...

Alcon plans to acquire STAAR Surgical through a definitive merger agreement, according to a press release. The acquisition is ...

Disc hemorrhage location was associated with areas of clustered visual field progression in patients with primary open-angle ...

A novel machine learning algorithm has potential to improve detection and treatment of individuals with familial ...

Direct telephone assistance may help mitigate systemic bias in electronic patient-reported outcome measure follow-up and ...

Children and adolescents with type 2 diabetes had greater reductions in HbA1c with an oral SGLT2 inhibitor compared with ...

U.S. News & World Report has named NYU Langone Hospitals as No. 1 in Best Hospitals for pulmonology and lung surgery. In last ...

ACG has voiced concerns about CMS’ proposed payment rates for physician services in 2026, which includes an “efficiency ...

Among adults with allergic rhinitis, a pharmacist-led education intervention contributed to improvements in symptom control ...

In this video, Philip J. Mease, MD, discusses results from phase 3 clinical trials of deucravacitinib for psoriatic arthritis, presented at the EULAR 2025 Congress.

In this video, Philip J. Mease, MD, director of rheumatology research at Providence Swedish Medical Center, in Seattle, discusses results from phase 3b clinical trials of guselkumab.The data, ...